The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018

Paolo A Ascierto; Lisa H Butterfield; Sandra Demaria; Robert L Ferris; Gordon J Freeman; Roger S Lo; Alberto Mantovani; Paul Nathan; Omid Hamid; Katerina Politi; Igor Puzanov

doi:10.1186/s40425-019-0683-0

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018

J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0.

Authors

Paolo A Ascierto¹, Lisa H Butterfield², Sandra Demaria³, Robert L Ferris⁴, Gordon J Freeman⁵, Roger S Lo⁶, Alberto Mantovani^{7

8}, Paul Nathan⁹, Omid Hamid¹⁰, Katerina Politi¹¹, Igor Puzanov¹²

Affiliations

¹ Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy. [email protected].
² Parker Institute for Cancer Immunotherapy Research Center, UCSF, San Francisco, California, USA.
³ Radiation Oncology, Department of Pathology, Weill Cornell Medical College, New York City, New York, USA.
⁴ UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachussetts, USA.
⁶ Melanoma Clinic, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
⁷ Humanitas University, Rozzano (Milan), Italy.
⁸ William Harvey Research Institute, Queen Mary University, London, UK.
⁹ Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
¹⁰ Clinical Research and Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, California, USA.
¹¹ Department of Pathology and Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
¹² Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA.

Abstract

As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate immunity in the anti-cancer immune response; the merits of combination versus sequential immunotherapy regimens in the treatment of cancer; the advantages and disadvantages of murine models of cancer versus humans in order to evaluate immunotherapy; and whether or not mechanisms of resistance to immunotherapy differ between different cancers. Discussion of these important topics are summarised in this report.

Keywords: Anti-CTLA-4; Anti-PD-1; Cancer; Combination therapy; Immunity; Immunotherapy; Treatment resistance.

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding